2 Reasons for developing guidance on SeQuent Please
|
|
- Hilary McLaughlin
- 7 years ago
- Views:
Transcription
1 NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE CENTRE FOR HEALTH TECHNOLOGY EVALUATION EVALUATION PATHWAY PROGRAMME FOR MEDICAL TECHNOLOGIES 1 Technology Medical technologies guidance SCOPE SeQuent Please coronary balloon catheter 1.1 Description of the technology SeQuent Please is a coronary balloon catheter for percutaneous transluminal coronary angioplasty. The balloon section of the distal end of the catheter is coated with paclitaxel at a dose of 3 microgram/mm 2. The balloon is expanded for approximately 30 seconds and paclitaxel is released into the vessel wall. Paclitaxel is an antimitotic agent, thereby leading to a reduction in smooth muscle cell proliferation that can result in restenosis and a recurrence of angina symptoms. The aim of targeted delivery is to ensure that the drug remains in the vessel wall. The balloon catheter is also coated in iopromide, an X-ray contrast medium which improves the solubility and transfer of paclitaxel to the vessel wall. SeQuent Please combines balloon angioplasty with local delivery of paclitaxel to treat small calibre coronary artery stenosis or a restenotic lesion in a previously stented coronary artery. The aim is to reduce the incidence of restenosis. This scope covers SeQuent Please for use in restenotic lesions or in small calibre coronary arteries in a previously stented coronary artery. 1.2 Regulatory status SeQuent Please is CE marked for use within the coronary arteries for primary angioplasty within bare-metal stents and for restenosis. 2 Reasons for developing guidance on SeQuent Please The Medical Technologies Advisory Committee (MTAC or the Committee ) recognised that SeQuent Please may be beneficial for selected patients, specifically those with in-stent restenosis or with stenoses of small calibre coronary arteries. Trial data support the superiority of SeQuent Please over uncoated balloons, drug-eluting stents and bare-metal stents in defined patient groups. 1
2 There is some evidence that SeQuent Please may reduce the incidence of restenosis, which could allow NHS resources to be reallocated. The manufacturer also claims that SeQuent Please can reduce the duration of anti-platelet therapy. The Committee considered SeQuent Please to be a potential treatment for patients with in-stent restenosis or stenoses in small calibre coronary arteries. The Committee was advised that other indications might include complex coronary disease (for example, left main stem lesions, branch lesions and vessel bifurcations) or in situations where standard stent use is undesirable (for example, in calcified vessels or tortuous anatomy). The Committee did not consider this technology suitable for primary treatment of stenotic lesions. The Committee considered that long-term cost savings could be achieved using this technology in selected patients through reduced restenosis rate and costs associated with re-intervention. The Committee noted that there are other developing technologies, such as biodegradable drug-eluting stents, and considered these to be potential future comparators. 3 Relevant diseases and conditions SeQuent Please is indicated for use in patients with coronary heart disease, specifically patients with either in-stent restenosis or small calibre coronary artery stenosis. Coronary heart disease is the most common cause of mortality in the UK, accounting for nearly 117,500 deaths in the UK in 2002 (approximately 103,000 deaths in England and Wales) (source: The rate of restenosis after drug-eluting stent is approximately 5% and for bare-metal stents the figure is approximately 15% (source: British Cardiovascular Intervention Society (BCIS) audit data and expert advisers). Other indications for use may include complex coronary disease (for example, left main stem lesions, branch lesions and vessel bifurcations) or in situations where standard stent use is undesirable (for example, in calcified vessels or tortuous anatomy). 4 Patient benefit 4.1 Current management options (the comparator) The patient group includes patients with coronary heart disease, specifically patients with either in-stent restenosis or small calibre coronary artery stenosis. Patients with complex coronary disease (for example, left main stem lesions, branch lesions and vessel bifurcations) or in situations where standard stent use is undesirable (for example, in calcified vessels or tortuous anatomy) may also benefit from treatment with SeQuent Please. Current treatment options for patients with in-stent restenosis include repeat balloon angioplasty, repeat stenting, cutting balloon angioplasty, directional coronary atherectomy, rotational coronary atherectomy, 2
3 brachytherapy and drug-eluting stent. However, in-stent restenosis is extremely difficult to manage. Current treatment options for small calibre coronary stenosis include percutaneous transluminal coronary angioplasty and stent implantation. Other paclitaxel-eluting balloons are also available. The manufacturer of SeQuent Please claims that if re-intervention is required after treatment with SeQuent Please, there are more treatment options available compared with using a stent because of the absence of an underlying metallic scaffold. 4.2 Clinical outcomes relevant to the technology The clinical outcomes relevant to the technology are restenosis, late lumen loss, recurrence of angina symptoms, quality of life and successful device placement, as well as death, device failure and other complications. 5 Care pathway and system impact outcomes 5.1 Care pathway impact The technology is primarily relevant to the scenarios of in-stent restenosis or small calibre artery stenosis. SeQuent Please could provide an additional treatment option in the care pathway of patients with in-stent restenosis or small coronary artery stenosis. This has the potential to lead to improved patient outcomes compared to current treatment options. No other issues relating to the care pathway, such as supporting equipment, additional training and necessary infrastructure, were identified. 5.2 System impact Compared with drug-eluting stents, SeQuent Please reduces the incidence of restenosis, and therefore the costs associated with retreatment and recurrence of angina symptoms, as well as the duration of antiplatelet therapy after the procedure. If re-intervention is required, the manufacturer claims that there will be a wider range of treatment strategies available after treatment with SeQuent Please, compared with stenting, because of the absence of an underlying metallic scaffold. 6 Health inequalities and equality impact 6.1 Health inequalities Mortality and morbidity rates associated with coronary heart disease vary by socioeconomic group (rates are higher in lower socioeconomic groups), by geographical area (rates are highest in Wales, North West England, and the Northern England and Yorkshire regions, and lowest in South East England) and by ethnic group (coronary heart disease rates are highest among people from the Indian subcontinent living in the UK). The prevalence of coronary heart disease increases with age and is higher in men than women. Coronary heart disease is more common in people with high serum cholesterol, high blood pressure, in people with type 1 or 2 3
4 diabetes, in people who smoke and in people who are physically inactive or obese. 6.2 Equality impact There is no evidence to demonstrate variation in effectiveness of SeQuent Please according to the age, gender, class or ethnicity of the target audience. There appears to be no differential impact on inequalities in health within and between different population groups. A medical technology evaluation of SeQuent Please is not likely to have an impact on the current burden of disease or to reduce inequalities in health. 7 Approach to cost measurement and health economic analysis The direct costs of Sequent Please are the price of the device and the costs of co-medication. The direct costs of the comparator are the same. The list price of SeQuent Please (device only) is 1035 plus three months comedication (clopidogrel) costs of 120. The list price of the comparator paclitaxel-eluting stent is approximately 750 for the device plus clopidogrel co-medication costs of 480 for 12 months of treatment. Co-medication costs after using SeQuent Please are reduced because drug therapy is required for a shorter period after treatment. Surgical time is not expected to differ significantly between SeQuent Please and its comparators at the first operative procedure. The cost analysis should begin after the patient has been diagnosed with symptomatic restenosis or when treatment is indicated for symptomatic and small vessel coronary artery disease. The analysis should take into account initial hospital care (surgical time and recovery), and the long-term management of the disease. Adverse events relating to use of the device (including re-intervention) and co-medication should be considered. 8 External organisations 8.1 Professional organisations Specialist societies contacted for Expert advice British Cardiovascular Intervention Society Societies or organisations for consultation British Cardiovascular Intervention Society British Cardiovascular Society 8.2 Patient organisations NICE s Patient and Public Involvement Programme contacted the following organizations for patient commentary: Action Heart 4
5 Arrhythmia Alliance British Cardiac Patients Association British Cardiovascular Society British Heart Foundation Cardiomyopathy Association Circulation Foundation CORDA Counsel and Care Grown Up Congenital Heart Patients Association HEART UK Heartcare Partnership UK National Heart Forum (UK) Royal College of Surgeons Patient Liaison Group SADS UK Vascular Society. 8.3 NHS trusts or other organisations with experience of the technology At the time of briefing note completion, SeQuent Please was understood by NICE to be being used at the following hospitals: Blackpool Victoria Hospital BMI hospitals, Manchester and Coventry Freeman Hospital, Newcastle Frenchay Hospital, Bristol James Cook University Hospital, Middlesbrough Leeds General Infirmary The Lister Hospital, Stevenage Liverpool Heart and Chest Hospital Manchester Royal Infirmary Morriston Hospital, Swansea Norfolk and& Norwich University hospital The Northern General Hospital, Sheffield The Queen Elizabeth Hospital, Birmingham Royal Cornwall Hospital The Walsgrave Hospital, Coventry Wythenshawe Hospital, South Manchester 9 Other issues Costs could vary significantly across regions because of commercial sensitivities and differences in purchasing contracts. 5
6 10 Related NICE guidance 10.1 Published Drug-eluting stents for the treatment of coronary artery disease. NICE technology appraisal guidance 152 (2008). Available from Ischaemic heart disease coronary artery stents (review). NICE technology appraisal guidance 71 (2003). Available from Under development None identified Suspended or terminated None identified. 11 Statement of the decision problem Population Intervention Comparator(s) Outcomes Cost analysis Subgroups to be considered Special considerations, including issues related to equity or equality Final scope issued by NICE Patients with in-stent restenosis and patients with small calibre coronary artery stenosis. SeQuent Please iopromide/paclitaxel-eluting balloon catheter for percutaneous transluminal coronary angioplasty. For in-stent restenosis: Repeat balloon angioplasty, repeat stenting, cutting balloon angioplasty, directional coronary atherectomy, rotational coronary atherectomy, brachytherapy and drug-eluting stents. For small calibre coronary stenosis: percutaneous transluminal coronary angioplasty and stent implantation. Restenosis, late lumen loss, recurrence of angina symptoms, quality of life, successful device placement. Death, device failure, other complications. Comparative cost analysis of SeQuent Please and the relevant UK comparator(s) for the treatment of symptomatic restenosis and symptomatic small vessel coronary artery disease. Cost analysis should account for hospital care, long-term disease management, adverse events (including re-intervention) and co-medications, including the longterm costs. Patients with complex coronary disease (for example, left main stem lesions, branch lesions and vessel bifurcations) or in situations where standard stent use is undesirable (for example, in calcified vessels or tortuous anatomy). No special considerations. 6
SeQuent Please balloon catheter for in-stent coronary restenosis. NICE medical technology guidance 1. Issue date: December 2010
Issue date: December 2010 SeQuent Please balloon catheter for in-stent coronary restenosis NICE medical technology guidance 1 1 NICE medical technology guidance 1 NICE medical technology guidance 1 SeQuent
More informationMEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE
DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:
More informationA Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs
A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory
More informationSAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014
Asia-Pacific Interventional Cardiology Procedures Outlook to 2020 Reference Code: GDMECR0061PDB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationSubmission to Senate Community Affairs Committee. Out-of-pocket costs in Australian healthcare. 12 May 2014
Submission to Senate Community Affairs Committee Out-of-pocket costs in Australian healthcare 12 May 2014 1 mtaa.org.au Medical technology for a healthier Australia Executive Summary The Medical Technology
More informationCatheter insertion of a new aortic valve to treat aortic stenosis
Issue date March 2012 Understanding NICE guidance Information for people who use NHS services NICE interventional procedures guidance advises the NHS on when and how new procedures can be used in clinical
More informationUnderstanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options. A Guide for Patients
Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options A Guide for Patients Coronary Artery Disease If you or a member of your family has been diagnosed with coronary artery
More informationThe National Service Framework for Cardiac Disease: Strategic Aims and Implementation A Cardiac Work Programme for Wales
The National Service Framework for Disease: Strategic Aims and A Work Programme for Wales Disease Strategic Framework 2008-11 1 CONTENTS Page 1. Introduction 3 2. Part 1 Strategic Aims 3 3. Part 2 Standard
More informationDrug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam
Drug-Eluting Balloons Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Potential conflicts of interest Speaker s name: Klaus Bonaventura
More informationTAXUS Express 2. Paclitaxel-Eluting Coronary Stent System. Patient Information Guide
TAXUS Express 2 Paclitaxel-Eluting Coronary Stent System Patient Information Guide 1 Table of Contents Coronary Artery Disease...2 Who Is at Risk?...3 Diagnosis of Coronary Artery Disease...3 Treatment
More information3.5% 3.0% 3.0% 2.4% Prevalence 2.0% 1.5% 1.0% 0.5% 0.0%
S What is Heart Failure? 1,2,3 Heart failure, sometimes called congestive heart failure, develops over many years and results when the heart muscle struggles to supply the required oxygen-rich blood to
More informationChristopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona
Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Areas to be covered Historical, current, and future treatments for various cardiovascular disease: Atherosclerosis (Coronary
More informationUNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator(s)
UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator(s) Pilot QOF indicator: The percentage of patients 79
More informationWhat is a Heart Attack? 1,2,3
S What is a Heart Attack? 1,2,3 Heart attacks, otherwise known as myocardial infarctions, are caused when the blood supply to a section of the heart is suddenly disrupted. Without the oxygen supplied by
More informationIs Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?
Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? --- NIRS-IVUS TVC Imaging Adds Additional Information for the Heart Team Dr. Luis Tami Memorial Regional Hospital
More informationGENERAL HEART DISEASE KNOW THE FACTS
GENERAL HEART DISEASE KNOW THE FACTS WHAT IS Heart disease is a broad term meaning any disease affecting the heart. It is commonly used to refer to coronary heart disease (CHD), a more specific term to
More informationCoronary Heart Disease (CHD) Brief
Coronary Heart Disease (CHD) Brief What is Coronary Heart Disease? Coronary Heart Disease (CHD), also called coronary artery disease 1, is the most common heart condition in the United States. It occurs
More informationPATIENT INFORMATION BOOKLET
PATIENT INFORMATION BOOKLET Wingspan Stent System with Gateway PTA Balloon Catheter TABLE OF CONTENTS Definitions... 2 What is the Purpose of This Booklet?... 3 What is an Intracranial Lesion?... 3 Who
More informationThe Bioresorbable Vascular Stent Dr Albert Ko
The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of
More informationRivaroxaban for acute coronary syndromes
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
More informationANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
More informationGuidance on the use of coronary artery stents
NHS National Institute for Clinical Excellence Guidance on the use of coronary artery stents Technology Appraisal 71 October 2003 Technology Appraisal Guidance 71 Guidance on the use of coronary artery
More informationCARDIAC CARE. Giving you every advantage
CARDIAC CARE Giving you every advantage Getting to the heart of the matter The Cardiovascular Program at Northwest Hospital & Medical Center is dedicated to the management of cardiovascular disease. The
More informationCoronary angiogram : An author view Patwary MSR
The ORION Medical Journal 2008 Sep;31:599-601 Coronary angiogram : An author view Patwary MSR Abstract It is relatively safe, though minimally invasive, test. Coronary angiogram is an x-ray of the coronary
More information4. Does your PCT provide structured education programmes for people with type 2 diabetes?
PCT Prescribing Report Drugs used in Type 2 Diabetes Discussion Points 1. Does your PCT have a strategy for prevention of type 2 diabetes? Does your PCT provide the sort of intensive multifactorial lifestyle
More informationAngioplasty and Stent Education Guide
Angioplasty and Stent Education Guide Table of Contents Treating coronary artery disease...2 What is coronary artery disease...3 Coronary artery disease treatment options...4 What are coronary artery
More informationCardiac Rehabilitation... recovery or by-pass? National Campaign for Cardiac Rehabilitation. beating heart disease together
Cardiac Rehabilitation... recovery or by-pass? beating heart disease together 1 What is the campaign calling for? 5aims The National Campaign for Cardiac Rehabilitation has five aims: that every heart
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationCardiac Rehab. Home. www.homecareforyou.com. Do you suffer from a cardiac condition that is limiting your independence in household mobility?
TM Nightingale Home Cardiac Rehab Do you suffer from a cardiac condition that is limiting your independence in household mobility? Such as, 1. A recent heart attack 2. A heart condition coronary artery
More informationMajestic Trial 12 Month Results
Majestic Trial 12 Month Results S.Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA ACADEMIC HOSPITALS Flensburg of Kiel University Ev.-Luth. Diakonissenanstalt zu Flensburg Knuthstraße 1, 24939 FLENSBURG Dept.
More informationEthnic Minorities, Refugees and Migrant Communities: physical activity and health
Ethnic Minorities, Refugees and Migrant Communities: physical activity and health July 2007 Introduction This briefing paper was put together by Sporting Equals. Sporting Equals exists to address racial
More informationHeart Attack: What You Need to Know
A WorkLife4You Guide Heart Attack: What You Need to Know What is a Heart Attack? The heart works 24 hours a day, pumping oxygen and nutrient-rich blood to the body. Blood is supplied to the heart through
More informationUnderstanding your Renal Stent Procedure. A patient Guide (COVER PAGE) TABLE OF CONTENTS (inside front page)
Understanding your Renal Stent Procedure. A patient Guide (COVER PAGE) TABLE OF CONTENTS (inside front page) The Kidney and the Renal Arteries... 1 Renal Artery Disease... 2 Diagnosis of Renal.Artery Disease...
More informationClinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up
Hellenic J Cardiol 45: 379-383, 2004 Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up PETROS S. DARDAS, DIMITRIS
More informationDescription of problem Description of proposed amendment Justification for amendment ERG response
KEY INACCURACIES Issue 1 Distinguishing between groups of STEMI patients Key issue throughout the report The ERG distinguishes between groups of STEMI patients defining four patient groups: STEMI without
More informationTAXUS Express2 Paclitaxel-Eluting Coronary Stent System TAXUS Liberté Paclitaxel-Eluting Coronary Stent System. A Patient s Guide
TAXUS Express2 Paclitaxel-Eluting Coronary Stent System TAXUS Liberté Paclitaxel-Eluting Coronary Stent System A Patient s Guide Table of Contents Coronary Artery Disease... 2 Who Is at Risk?... 3 Diagnosis
More informationPHYSICAL ACTIVITY STATISTICS 2015
PHYSICAL ACTIVITY STATISTICS 2015 British Heart Foundation Centre on Population Approaches for Non Communicable Disease Prevention. Nuffield Department of Population Health, University of Oxford In Northern
More informationFewer people with coronary heart disease are being diagnosed as compared to the expected figures.
JSNA Coronary heart disease 1) Key points 2) Introduction 3) National picture 4) Local picture of CHD prevalence 5) Mortality from coronary heart disease in Suffolk County 6) Trends in mortality rates
More informationCilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
More informationStroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012
Faculty Prevention Sharon Ewer, RN, BSN, CNRN Stroke Program Coordinator Baptist Health Montgomery, Alabama Satellite Conference and Live Webcast Monday, May 21, 2012 2:00 4:00 p.m. Central Time Produced
More informationReview of diabetes care in London Health and Environment Committee
The London Assembly s Health and Environment Committee intends to review diabetes care in London. Aim of review The purpose of this review is for the Committee to understand the extent of diabetes prevalence
More informationCalifornia Health and Safety Code, Section 1256.01
California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program
More informationSCORM. For more patient education, please visit www.cypherusa.com
Attach Label Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options Stent Implant Card CYPHER Sirolimus-eluting Coronary Stent SCORM P.O. Box 025700 Miami, FL 33102-5700,
More informationNOVOSTE BETA-CATH SYSTEM
HOSPITAL INPATIENT AND OUTPATIENT BILLING GUIDE FOR THE NOVOSTE BETA-CATH SYSTEM INTRAVASCULAR BRACHYTHERAPY DEVICE This guide is intended solely for use as a tool to help hospital billing staff resolve
More informationCARDIOVASCULAR DISEASE STATISTICS 2014
CARDIOVASCULAR DISEASE STATISTICS 2014 British Heart Foundation Centre on Population Approaches for Non Communicable Disease Prevention. Nuffield Department of Population Health, University of Oxford PREMATURE
More informationGUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA - A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES -
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.1 Appendix 1 December 2008 GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA
More informationNational Diabetes Audit 2013-2014 and 2014-2015 Report 1: Care Processes and Treatment Targets. Version 1.0 Published: 28 January 2016
National Diabetes Audit 2013-2014 and 2014-2015 Report 1: Care Processes and Treatment Targets Version 1.0 Published: 28 January 2016 Introduction The National Diabetes Audit (NDA) continues to provide
More informationCoronary Artery Disease leading cause of morbidity & mortality in industrialised nations.
INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationPerioperative Cardiac Evaluation
Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project
More informationSocial Care and Obesity
Social Care and Obesity A discussion paper Health, adult social care and ageing Introduction The number of obese people in England has been rising steadily for the best part of 20 years. Today one in four
More information2015 European Coronary Stent New Product Innovation Award
2015 European Coronary Stent New Product Innovation Award 2015 Contents Background and Company Performance... 3 Industry Challenges... 3 New Product Attributes and Customer Impact... 3 Conclusion... 4
More informationCoronary Stents. What is a Coronary Artery stent?
What is a Coronary Artery stent? Coronary Stents A coronary stent is stainless tube with slots. It is mounted on a balloon catheter in a "crimped" or collapsed state. When the balloon of is inflated, the
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More informationStatus of Drug-Eluting Coronary Stents
Status of Drug-Eluting Coronary Stents EVOLUTION OF PERCUTANEOUS CORONARY INTERVENTIONAL TECHNOLOGIES The introduction of percutaneous transluminal coronary angioplasty (PTCA) in the late1970s provided
More informationVertebrobasilar Disease
The Vascular Surgery team at the University of Michigan is dedicated to providing exceptional treatments for in the U-M Cardiovascular Center (CVC), our new state-of-the-art clinical facility. Treatment
More informationNational Assembly for Wales: Health and Social Care Committee
2 Ashtree Court, Woodsy Close Cardiff Gate Business Park Cardiff CF23 8RW Tel: 029 2073 0310 wales@rpharms.com www.rpharms.com 18 th October 2011 Submission to: Call for Evidence: Response from: National
More informationA Patient s Guide to Minimally Invasive Abdominal Aortic Aneurysm Repair
A Patient s Guide to Minimally Invasive Abdominal Aortic Aneurysm Repair Table of Contents The AFX Endovascular AAA System............................................ 1 What is an Abdominal Aortic Aneurysm
More informationCardiac Rehabilitation
Cardiac Rehabilitation Cardiac Rehabilitation Most patients return to usual activities within a few months after a heart attack and/or surgery. Cardiac rehabilitation (rehab) monitors and assists you
More informationIdentifying and treating long-term kidney problems (chronic kidney disease)
Understanding NICE guidance Information for people who use NHS services Identifying and treating long-term kidney problems (chronic kidney disease) NICE clinical guidelines advise the NHS on caring for
More informationPUBLIC HEALTH PROGRAMME GUIDANCE DRAFT SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE PUBLIC HEALTH PROGRAMME GUIDANCE DRAFT SCOPE 1 Guidance title Guidance for primary care services and employers on the management of long-term sickness
More informationRenal Artery Stenosis Treatments. A Guide for Consumers
Renal Artery Stenosis Treatments A Guide for Consumers Fast Facts on Renal Artery Stenosis treatments Renal artery stenosis (RAS) is a narrowing of one or both of the blood vessels to the kidneys. RAS
More informationAbdominal Aortic Aneurysm (AAA) General Information. Patient information Leaflet
Abdominal Aortic Aneurysm (AAA) General Information Patient information Leaflet 1 st July 2016 WHAT IS THE AORTA? The aorta is the largest artery (blood vessel) in the body. It carries blood from the heart
More informationClinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b
Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy Statement: Percutaneous
More informationHeart information. Cardiac rehabilitation
Heart information Cardiac rehabilitation Contents 2 What is cardiac rehabilitation? 3 What are the benefits of cardiac rehabilitation? 4 Who should take part in cardiac rehabilitation? 4 When does cardiac
More informationA Patient Information Guide for the CYPHER Sirolimus-eluting Coronary Stent
bringing evidence to life Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options A Patient Information Guide for the CYPHER Sirolimus-eluting Coronary Stent Patient s Name
More informationScottish Diabetes Survey 2014. Scottish Diabetes Survey Monitoring Group
Scottish Diabetes Survey 2014 Scottish Diabetes Survey Monitoring Group Contents Table of Contents Contents... 2 Foreword... 4 Executive Summary... 6 Prevalence... 8 Undiagnosed diabetes... 21 Duration
More informationPress. Siemens solutions support diagnosis and treatment of cardiovascular diseases
Press Healthcare Erlangen, August 29, 2015 ESC 2015: ExCel London Exhibition and Convention Center, Booth #G700 Siemens solutions support diagnosis and treatment of cardiovascular diseases New cardiovascular
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationSTONY BROOK UNIVERSITY HOSPITAL VASCULAR CENTER CREDENTIALING POLICY
STONY BROOK UNIVERSITY HOSPITAL VASCULAR CENTER CREDENTIALING POLICY Per Medical Board decision March 18, 2008: These credentialing standards do NOT apply to peripheral angiography performed in the context
More informationRecovering From Heart Problems Through Cardiac Rehabilitation: Patient Guide The Keys to Heart Health
Recovering From Heart Problems Through Cardiac Rehabilitation: Patient Guide The Keys to Heart Health Exercise: Education: Counseling: Regular physical activity that is tailored to your abilities, needs,
More informationA MANIFESTO FOR BETTER MENTAL HEALTH
A MANIFESTO FOR BETTER MENTAL HEALTH The Mental Health Policy Group General Election 2015 THE ROAD TO 2020 The challenge and the opportunity for the next Government is clear. If we take steps to improve
More informationCARDIOLOGIST What does a cardiologist do? A cardiologist is a doctor who specializes in caring for your heart and blood vessel health.
YOUR TREATMENT TEAM CARDIOLOGIST What does a cardiologist do? A cardiologist is a doctor who specializes in caring for your heart and blood vessel health. To become a cardiologist, a doctor completes additional
More informationOstial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI
Ostial LAD: Single stent approach is the best Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Chair, Interventional Cardiology Sanatorio San Lucas Instituto Alexander Fleming Buenos
More informationMISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY
MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY In order to improve the efficiency of PINNACLE Registry data analytics, a missing data analysis has been conducted on PINNACLE Registry data
More informationCh. 138 CARDIAC CATHETERIZATION SERVICES 28 138.1 CHAPTER 138. CARDIAC CATHETERIZATION SERVICES GENERAL PROVISIONS
Ch. 138 CARDIAC CATHETERIZATION SERVICES 28 138.1 CHAPTER 138. CARDIAC CATHETERIZATION SERVICES Sec. 138.1 Principle. 138.2. Definitions. GENERAL PROVISIONS PROGRAM, SERVICE, PERSONNEL AND AGREEMENT REQUIREMENTS
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationFY2015 Final Hospital Inpatient Rule Summary
FY2015 Final Hospital Inpatient Rule Summary Interventional Cardiology (IC) Peripheral Interventions (PI) Rhythm Management (RM) On August 4, 2014, the Centers for Medicare & Medicaid Services (CMS) released
More informationHeart Attack Your quick guide
Heart Attack Your quick guide Coronary heart disease is the UK s single biggest killer. For over 50 years we ve pioneered research that s transformed the lives of people living with heart and circulatory
More informationneeds, said Overlake Executive Vice President and Chief Operating Officer David Schultz
With treatments only found at Overlake, Overlake attributes its sustained success to forward thinking and services tailored to the Eastside community. By James McIntosh Overlake Medical Center is the preferred
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Remit / Appraisal objective: Final scope To appraise the clinical and cost effectiveness of
More informationAdvances in Stent Technology
Nurse/Technologist Symposium Advances in Stent Technology Antonietta Tolentino, CCRN, MSN, ANP-C Adult Nurse Practitioner, Cardiac Catheterization Laboratory The Zena and Michael A. Weiner Cardiovascular
More informationEverolimus Eluting Coronary Stent System. Patient Information Guide
Everolimus Eluting Coronary Stent System Patient Information Guide Table of Contents Coronary Artery Disease (CAD)...5 Your Heart...5 What is CAD?...5 What are the Symptoms of CAD?...5 What are the Risk
More informationKIH Cardiac Rehabilitation Program
KIH Cardiac Rehabilitation Program For any further information Contact: +92-51-2870361-3, 2271154 Feedback@kih.com.pk What is Cardiac Rehabilitation Cardiac rehabilitation describes all measures used to
More informationCORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ. Charles White MD
CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ Charles White MD Director of Thoracic Imaging Department of Radiology University of Maryland CORONARY ARTERY BYPASS GRAFTS First performed
More informationECONOMIC COSTS OF PHYSICAL INACTIVITY
ECONOMIC COSTS OF PHYSICAL INACTIVITY This fact sheet highlights the prevalence and health-consequences of physical inactivity and summarises some of the key facts and figures on the economic costs of
More informationCohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationPRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
More informationYukon Choice DES + Translumina - The polymer-free DES solution. www.translumina.de. Coronary Stent System for Drug Application
Coronary Stent System for Drug Application Yukon Choice DES + new catheter polymer-free DES Translumina - The polymer-free DES solution www.translumina.de A First Class Stent The YUKON Choice DES+ is the
More informationNow we ve weighed up your application for our protection products, it s only fair we talk you through our assessment process. More than anything, we
how we assess your application UNDERWRITING EXPLAINED. Now we ve weighed up your application for our protection products, it s only fair we talk you through our assessment process. More than anything,
More informationRITMIR024 - STEM CELL RESEARCH IN CARDIOLOGY
1. SCOPE AND METHODOLOGY 2. REPORT SYNOPSIS 2.1 General Definitions Myoblasts Pluripotent Cells Multipotent Cells Progenitor Cells Role of Stem Cells in Repairing the Heart Stem Cell Therapy Stem Cells
More informationEpidemic of coronary heart disease and its treatment in Australia
Epidemic of coronary heart disease and its treatment in Australia The Australian Institute of Health and Welfare is Australia s national health and welfare statistics and information agency. The Institute
More informationDeterminants, Key Players and Possible Interventions
Major in Human Health, Nutrition and Environment, FS 2010 Public Health Concepts Determinants, Key Players and Possible Interventions David Fäh Aims Have an idea about which parameters can influence health
More informationDiabetes: Factsheet. Tower Hamlets Joint Strategic Needs Assessment 2010-2011. Executive Summary. Recommendations
Diabetes: Factsheet Tower Hamlets Joint Strategic Needs Assessment 2010-2011 Executive Summary Diabetes is a long term condition that affects 11,859 people in Tower Hamlets, as a result of high levels
More informationGRASP-AF Coming to a PCT near you.
GRASP-AF Coming to a PCT near you. ADAS Anticoagulation dosing advisory service Blackpool Teaching Hospitals Trust Sean O'Brien; Anticoagulation Specialist BMS Grasp-AF and the implications on our Anticoagulation
More informationINTRODUCTION TO EECP THERAPY
INTRODUCTION TO EECP THERAPY is an FDA cleared, Medicare approved, non-invasive medical therapy for the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and
More informationRenovascular Disease. Renal Artery and Arteriosclerosis
Other names: Renal Artery Stenosis (RAS) Renal Vascular Hypertension (RVH) Renal Artery Aneurysm (RAA) How does the normal kidney work? The blood passes through the kidneys to remove the body s waste.
More information